NCT07479485 2026-03-18
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Lepu Biopharma Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
9 trialsNCT07281664 2025-12-15
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT07128251 2025-08-17
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Phase 2 Not yet recruiting
NCT07012798 2025-06-10
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06530784 2024-07-31
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06041490 2023-09-18
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting